127 related articles for article (PubMed ID: 22309978)
1. Comparing three screening tools for drug-induced parkinsonism in patients with advanced schizophrenia: a pilot study.
Blanchet PJ; Normandeau L; Rompré PH
Schizophr Res; 2012 May; 137(1-3):230-3. PubMed ID: 22309978
[TBL] [Abstract][Full Text] [Related]
2. Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism.
Morley JF; Pawlowski SM; Kesari A; Maina I; Pantelyat A; Duda JE
Parkinsonism Relat Disord; 2014 Jul; 20(7):738-42. PubMed ID: 24742370
[TBL] [Abstract][Full Text] [Related]
3. Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia.
Jung HY; Kim JH; Ahn YM; Kim SC; Hwang SS; Kim YS
Hum Psychopharmacol; 2005 Jan; 20(1):41-5. PubMed ID: 15565639
[TBL] [Abstract][Full Text] [Related]
4. Using accelerometer as a diagnostic tool to detect drug-induced parkinsonism (DIP) secondary to first-generation anti-psychotic medications.
Trisno R; Nair P; Martin D; Baghini MS; Chung H; Pendharkar G; Kulkarni J
Australas Psychiatry; 2020 Jun; 28(3):348-353. PubMed ID: 32093499
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced parkinsonism: relationship to age at onset of schizophrenia.
Sandyk R; Kay SR
Funct Neurol; 1991; 6(2):151-7. PubMed ID: 1680777
[TBL] [Abstract][Full Text] [Related]
6. Clinimetric evaluation of the Simpson-Angus Scale in older adults with schizophrenia.
Blanchet PJ; Rompré PH
J Clin Psychopharmacol; 2014 Feb; 34(1):36-9. PubMed ID: 24145218
[TBL] [Abstract][Full Text] [Related]
7. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?
Lim TT; Ahmed A; Itin I; Gostkowski M; Rudolph J; Cooper S; Fernandez HH
Int J Neurosci; 2013 Mar; 123(3):170-4. PubMed ID: 23078283
[TBL] [Abstract][Full Text] [Related]
8. Neuroleptic-induced parkinsonism in older schizophrenics.
Hoffman WF; Labs SM; Casey DE
Biol Psychiatry; 1987 Apr; 22(4):427-39. PubMed ID: 2882787
[TBL] [Abstract][Full Text] [Related]
9. Absence of parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine.
Dhopesh V; Macfadden A; Maany I; Gamble G
Psychiatr Serv; 1997 Jan; 48(1):95-7. PubMed ID: 9117510
[TBL] [Abstract][Full Text] [Related]
10. A study of the early signs of drug induced parkinsonism.
Arblaster LA; Lakie M; Mutch WJ; Semple M
J Neurol Neurosurg Psychiatry; 1993 Mar; 56(3):301-3. PubMed ID: 8096240
[TBL] [Abstract][Full Text] [Related]
11. Parkinsonian axial signs in schizophrenia.
Morgante F; Barbui C; Tinazzi M;
Parkinsonism Relat Disord; 2017 Mar; 36():89-92. PubMed ID: 28038867
[TBL] [Abstract][Full Text] [Related]
12. [Drug-induced parkinsonism. Clinical aspects compared with Parkinson disease].
Errea-Abad JM; Ara-Callizo JR; Aibar-Remón C
Rev Neurol; 1998 Jul; 27(155):35-9. PubMed ID: 9674021
[TBL] [Abstract][Full Text] [Related]
13. Asymmetry in clinical features of drug-induced parkinsonism.
Sethi KD; Zamrini EY
J Neuropsychiatry Clin Neurosci; 1990; 2(1):64-6. PubMed ID: 1983774
[TBL] [Abstract][Full Text] [Related]
14. HLA antigens in drug-induced parkinsonism.
Metzer WS; Newton JE; Steele RW; Claybrook M; Paige SR; McMillan DE; Hays S
Mov Disord; 1989; 4(2):121-8. PubMed ID: 2567491
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of neuroleptic-induced parkinsonism.
Hassin-Baer S; Sirota P; Korczyn AD; Treves TA; Epstein B; Shabtai H; Martin T; Litvinjuk Y; Giladi N
J Neural Transm (Vienna); 2001; 108(11):1299-308. PubMed ID: 11768628
[TBL] [Abstract][Full Text] [Related]
16. Electroconvulsive therapy in neuroleptic-induced parkinsonism.
Goswami U; Dutta S; Kuruvilla K; Papp E; Perenyi A
Biol Psychiatry; 1989 Jul; 26(3):234-8. PubMed ID: 2568133
[TBL] [Abstract][Full Text] [Related]
17. Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype.
Munhoz RP; Bertucci Filho D; Teive HA
Neurol Sci; 2017 Feb; 38(2):319-324. PubMed ID: 27853909
[TBL] [Abstract][Full Text] [Related]
18. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment.
Peralta V; Cuesta MJ; Martinez-Larrea A; Serrano JF
Am J Psychiatry; 2000 Sep; 157(9):1461-6. PubMed ID: 10964863
[TBL] [Abstract][Full Text] [Related]
19. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
[TBL] [Abstract][Full Text] [Related]
20. The influence of topography on the cognitive and psychopathological effects of tardive dyskinesia.
Brown KW; White T
Am J Psychiatry; 1992 Oct; 149(10):1385-9. PubMed ID: 1356314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
